News for XTL Biopharmaceuticals Ltd. (XTLB)

News for XTL Biopharmaceuticals Ltd.
Date Headline
Mar 22, 2017 09:22 AM XTL Biopharmaceuticals Announces Closing of $2.8 Million Private Placement From Existing Investors
Mar 07, 2017 12:40 PM XTL Biopharmaceuticals Announces $2.8 Million Private Placement From Existing Investors
Mar 01, 2017 08:30 AM XTL Biopharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Listing Requirement
Feb 17, 2017 08:00 AM XTL Biopharmaceuticals Announces $2.5 Million Registered Direct Offering
Feb 13, 2017 09:08 AM XTL Biopharmaceuticals Expands Clinical Advisory Board to Support Phase II Study of HCDR1 in Sjogren's Syndrome
Jan 25, 2017 08:30 AM XTL Biopharmaceuticals Announces Ratio Change of its Depositary Receipt Program
Jan 05, 2017 08:30 AM XTL Biopharmaceuticals' Preclinical Studies of hCDR1 Demonstrate Therapeutic Potental In the Treatment of Sjögren's Syndrome
Dec 19, 2016 08:00 AM XTL Biopharmaceuticals to Present at Biotech Showcase
Dec 06, 2016 08:30 AM XTL Biopharmaceuticals Reports Third Quarter 2016 Financial Results & Provides Clinical and Operational Update
Nov 09, 2016 01:25 PM XTL Biopharmaceuticals Receives NASDAQ Notification Regarding Minimum Bid Requirements